STOCK TITAN

RTW funds report 69.6M Zai Lab (ZLAB) shares beneficially owned

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

RTW Investments and Roderick Wong filed a Schedule 13G reporting beneficial ownership of 69,590,320 ordinary shares of Zai Lab Limited, equal to 6.3% of the class. The ownership is held through RTW-managed funds, with RTW and Dr. Wong sharing voting and dispositive power over these shares.

The percentage is based on 1,105,937,600 ordinary shares outstanding as of October 31, 2025, as disclosed in Zai Lab’s Form 10-Q. The filing notes that each American Depositary Share represents ten ordinary shares and states the position is held in the ordinary course of business, not for the purpose of influencing control of the company.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RTW Investments, LP
Signature:/s/ Roderick Wong, M.D.
Name/Title:By Roderick Wong, M.D., Managing Partner
Date:02/17/2026
Roderick Wong
Signature:/s/ Roderick Wong, M.D.
Name/Title:Roderick Wong, M.D.
Date:02/17/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement

FAQ

What stake in Zai Lab (ZLAB) does RTW Investments report on this Schedule 13G?

RTW Investments and Roderick Wong report beneficial ownership of 69,590,320 ordinary shares of Zai Lab, representing 6.3% of the outstanding class. The stake is held through RTW-managed funds, with shared voting and dispositive power over the reported shares.

How was RTW’s 6.3% ownership in Zai Lab (ZLAB) calculated?

The 6.3% ownership is calculated using 1,105,937,600 ordinary shares outstanding as of October 31, 2025, as disclosed in Zai Lab’s Form 10-Q. RTW’s reported beneficial ownership of 69,590,320 shares is measured against this outstanding share count.

Who are the reporting persons on the Zai Lab (ZLAB) Schedule 13G filing?

The reporting persons are RTW Investments, LP and Roderick Wong, M.D.. RTW acts as investment adviser to certain funds holding Zai Lab shares, and Dr. Wong is RTW’s Managing Partner and Chief Investment Officer, sharing voting and dispositive power over the reported shares.

Are Zai Lab (ZLAB) American Depositary Shares or ordinary shares reported in this filing?

The filing reports ordinary shares, noting there is no CUSIP for these shares. CUSIP 98887Q104 applies to Zai Lab’s American Depositary Shares (ADSs), and each ADS represents ten ordinary shares, clarifying the relationship between the securities classes.

Is RTW’s Zai Lab (ZLAB) position intended to influence control of the company?

The filing certifies the securities were acquired and held in the ordinary course of business. It states they were not acquired and are not held for the purpose of changing or influencing control of Zai Lab, other than activities tied to certain nomination rules.

Who has the right to dividends or sale proceeds from the Zai Lab (ZLAB) shares reported by RTW?

The filing states that the RTW Funds have the right to receive, or direct the receipt of, dividends and sale proceeds from the reported Zai Lab shares. RTW and Dr. Wong report beneficial ownership through their roles related to these investment funds.
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

2.25B
106.96M
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI